Navigation Links
Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
Date:1/9/2008

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to NPS Pharmaceuticals on its recently-completed partnering of Gattex(TM) (teduglutide) with Nycomed. Under the terms of the agreement, NPS has licensed rights to Gattex outside North America to Nycomed for the treatment of gastrointestinal disorders.

Gattex is a GLP-2 analog in development for the treatment of short-bowel syndrome (SBS). SBS can result from one or more bowel surgeries related to inflammatory bowel disease or injury. In a recent Phase III trial, patients in the low dose Gattex group showed a statistically significant reduction in parenteral nutrition vs. placebo, while the high dose group showed a trend in the difference between the treatment group and placebo, but this did not reach statistical significance. NPS is also pursuing development of Gattex as a possible treatment for chemotherapy-induced gastrointestinal mucositis in cancer patients and necrotizing enterocolitis in preterm infants.

Under the terms of the agreement, NPS and Nycomed will share future development costs 50:50. NPS maintains commercialization rights for the product in the US, Canada, and Mexico.

The agreement includes an upfront payment to NPS of $35 million, and combined development and sales milestones that could potentially total more than $150 million in additional payments from Nycomed. Royalties to NPS for sales in Nycomed's territories, although not publicly disclosed, are in the double-digit range.

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:

-- Mergers & Acquisitions

-- Strategic Partnering from preclinical research to product development

and commercialization

-- Spin-Outs and Divestitures

-- Financing (Private Placements)

-- Advisory Services to define the role of transactions in achieving

strategic objectives

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. The company's 60 person scientific and business team, supported by its 40-person Advisory Boards, the strategic and financial network of its limited partners, and the close relationships developed with numerous life sciences companies and management, provide Burrill with unparalleled access and insight.

Burrill is the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publishes a wide range of bio-intelligence reports including: The Personalized Medicine Report, The Stem Cell Report, and periodic newsletters covering Canada, China, Europe, India, Japan and Partnering/M&A. In association with the California Healthcare Institute, Burrill publishes The Journal of Life Sciences -- a bimonthly magazine. Burrill's flagship publication is its annual "State of the Industry" report, the most recent 21st Edition being Biotech 2007: Life Sciences -- A Global Transformation. The 22nd Edition is entitled Biotech 2008: Life Sciences -- A 20/20 Vision to 2020, available 1Q '08. These publications provide the latest insight, intelligence and information on the life sciences industry.

http://www.burrillandco.com.


'/>"/>
SOURCE Burrill Merchant Banking
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Burrill & Company Announces Promotions
2. The 3rd Annual Burrill Personalized Medicine Meeting November 12-13, 2007 in San Francisco
3. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
7. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
11. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... For the ... has produced a Spotlight series on “Cell Therapy Regulation” for its ... leading experts on the unique regulatory challenges of stem cell medical research. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... CTNext , Connecticut’s ... has formed a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of ... other high-ranking representatives from 35 higher education institutions across the state over the ...
(Date:6/20/2017)... Parsippany, NJ (PRWEB) , ... June 20, 2017 , ... ... OHAUS makes the transition from being a trusted supplier in the weighing industry, to ... including cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy honey bees is like ... delivering pollen and nectar containing nutrients necessary for growth and survival. Better nutrition gives ... recent indicators point to a decline in honey bee health. Sick and weakened bees ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):